Group One Trading’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-200
| Closed | -$1K | – | 5669 |
|
|
2017
Q4 | $1K | Buy |
+200
| New | +$819 | ﹤0.01% | 4774 |
|
|
2017
Q3 | – | Sell |
-6,400
| Closed | -$24K | – | 5460 |
|
|
2017
Q2 | $24K | Buy |
6,400
+2,900
| +83% | +$11.5K | ﹤0.01% | 3882 |
|
|
2017
Q1 | $14K | Sell |
3,500
-4,800
| -58% | -$20.2K | ﹤0.01% | 4029 |
|
|
2016
Q4 | $36K | Buy |
8,300
+2,700
| +48% | +$17.5K | ﹤0.01% | 3450 |
|
|
2016
Q3 | $55K | Sell |
5,600
-5,450
| -49% | -$38.6K | ﹤0.01% | 3304 |
|
|
2016
Q2 | $63K | Sell |
11,050
-51,750
| -82% | -$351K | ﹤0.01% | 3163 |
|
|
2016
Q1 | $479K | Buy |
62,800
+53,450
| +572% | +$412K | 0.01% | 1718 |
|
|
2015
Q4 | $125K | Sell |
9,350
-2,183
| -19% | -$37.6K | ﹤0.01% | 2843 |
|
|
2015
Q3 | $190K | Sell |
11,533
-2,500
| -18% | -$51.3K | ﹤0.01% | 2542 |
|
|
2015
Q2 | $315K | Buy |
14,033
+13,350
| +1,955% | +$211K | ﹤0.01% | 2180 |
|
|
2015
Q1 | $7K | Sell |
683
-33,300
| -98% | -$327K | ﹤0.01% | 4276 |
|
|
2014
Q4 | $387K | Sell |
33,983
-1,717
| -5% | -$18.6K | 0.01% | 1759 |
|
|
2014
Q3 | $411K | Sell |
35,700
-14,050
| -28% | -$215K | 0.01% | 1768 |
|
|
2014
Q2 | $967K | Buy |
49,750
+13,217
| +36% | +$233K | 0.01% | 1159 |
|
|
2014
Q1 | $655K | Buy |
36,533
+12,683
| +53% | +$208K | 0.01% | 1432 |
|
|
2013
Q4 | $252K | Sell |
23,850
-7,350
| -24% | -$82.2K | ﹤0.01% | 2231 |
|
|
2013
Q3 | $386K | Sell |
31,200
-40,717
| -57% | -$429K | 0.01% | 1835 |
|
|
2013
Q2 | $673K | Buy |
+71,917
| New | +$924K | 0.02% | 1113 |
|
Group One Trading's CASC Position: Q1 2018 in Review
Group One Trading sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 593 shares — an estimated $2K sold.
Group One Trading first reported a position in CASC in Q2 2013 and held it in 16 quarters. The position peaked at $439K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Group One Trading reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Group One Trading sold 593 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
- Group One Trading first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
- Group One Trading's Cascadian Therapeutics, Inc. position peaked at $439K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Group One Trading's 13F filing for Q1 2018, filed 11 May 2018.